BioXcel Therapeutics, Inc.
Biopharmaceutical company using AI to develop drugs for neuroscience and immuno-oncology.
BTAI | US
Overview
Corporate Details
- ISIN(s):
- US09075P2048
- LEI:
- Country:
- United States of America
- Address:
- 555 LONG WHARF DRIVE, 6511 NEW HAVEN
- Sector:
- Manufacturing
Description
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company that utilizes a proprietary artificial intelligence (AI) platform for drug development. The company focuses on creating transformative medicines in the fields of neuroscience and immuno-oncology. Its AI-driven approach aims to identify new therapeutic uses for existing molecules and novel compounds, potentially accelerating development timelines. The company's lead commercial product is IGALMI™ (dexmedetomidine sublingual film), approved for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. BioXcel's late-stage clinical pipeline includes programs investigating treatments for agitation in patients with Alzheimer's disease and other neuropsychiatric conditions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all BioXcel Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BioXcel Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BioXcel Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
